Symptoms and General Pathology

All Conditions

Neoplasms

Digestive System Diseases

Disease Progression

Colorectal Neoplasms

Intestinal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Colonic Diseases

Intestinal Diseases

Rectal Diseases

Disease Attributes

Herbal and Botanical

All Drugs and Chemicals

Cola

This is an Interventional, Non Therapeutic arm

All patients will undergo FDG PET-CT at inclusion and 2 weeks after

FDG PET-CT

All patients will undergo Diffusion MRI at inclusion and 2 weeks later

Diffusion MRI

Blood samples (plasma preparation and CTC)

Amélie Deleporte, MD

The purpose of this study is to assess whether in a population of patients with advanced colorectal cancer for which no known effective therapy is available, measuring the spontaneous evolution of tumoral metabolic progression index by serial FGD PET-CT and Diffusion MRI can show that tumor growth rate is related to the patient's outcome, and that serial FDG PET-CT and Diffusion MRI are able to measure it.

Natural history of tumors is a poorly studied subject, the clinical evidence of some tumors aggressiveness as opposed to some other's indolent behavior has never been formally assessed in daily practice or in clinical studies and remains largely unpredictable. The patient's populations are in fact a mix between different tumoral phenotypes that while carrying the same apparent disease evolve with different outcomes.

We hypothesize that,in a population of patients with advanced colorectal cancer for which no known effective therapy is available, measuring the spontaneous evolution of tumoral metabolic progression index by serial FGD PET-CT and Diffusion MRI can show that tumor growth rate is related to the patient's outcome, and that serial FDG PET-CT and Diffusion MRI are able to measure it.

If the hypothesis is verified, this finding could:

* Allow to define therapeutic strategies according to the tumoral metabolic progression index.
* Limit the need for randomization in the early drug development phases as each patient could be considered as his own control.
* To stratify patients according to their baseline metabolic growth rate in randomized controlled trials with overall survival as an endpoint.

Correlating the Tumoral Metabolic Progression Index to Patient's Outcome in Advanced Colorectal Cancer

Correlating the Tumoral Metabolic Progression Index Measured by Serial FDG PET-CT and Apparent Diffusion Coefficient Measured by MRI to Patient's Outcome in Advanced Colorectal Cancer

Jules Bordet Institute

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Correlating the Tumoral Metabolic Progression Index to Patient's Outcome in Advanced Colorectal Cancer	NCT01591590	Colorectal Canc...	FDG PET-CT Diffusion MRI Blood samples (...	18 Years -	Jules Bordet Institute
Correlating the Tumoral Metabolic Progression Index to Patient's Outcome in Advanced Colorectal Cancer	NCT01591590	Colorectal Canc...	FDG PET-CT Diffusion MRI Blood samples (...	18 Years -	Jules Bordet Institute

Spots Global Cancer Trial Database for metabolic progression index